HUP0302119A2 - Use of baculovirus vectors in gene therapy - Google Patents

Use of baculovirus vectors in gene therapy

Info

Publication number
HUP0302119A2
HUP0302119A2 HU0302119A HUP0302119A HUP0302119A2 HU P0302119 A2 HUP0302119 A2 HU P0302119A2 HU 0302119 A HU0302119 A HU 0302119A HU P0302119 A HUP0302119 A HU P0302119A HU P0302119 A2 HUP0302119 A2 HU P0302119A2
Authority
HU
Hungary
Prior art keywords
gene therapy
baculovirus vectors
gene
vector
baculovirus
Prior art date
Application number
HU0302119A
Other languages
Hungarian (hu)
Inventor
Kari J. Airenne
Seppo Yla-Herttuala
Original Assignee
Ark Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Limited filed Critical Ark Therapeutics Limited
Publication of HUP0302119A2 publication Critical patent/HUP0302119A2/en
Publication of HUP0302119A3 publication Critical patent/HUP0302119A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A jelen találmány egy génterméket szállító eljárásra vonatkozik,amelyben a gén egy baculovírus-vektorba van behelyezve és a vektortolyan testrészhez alkalmazzuk, amely mentes vagy lényegében mentes avértől. A találmány továbbá egy eszközre is vonatkozik egy géntermékperiadventiciális szállítására, amelyben a gén egy baculovírus-vektorba van beépítve, amelyből expresszálódhat. ÓThe present invention relates to a method for delivering a gene product in which the gene is inserted into a baculovirus vector and applied to a vector-like body part that is free or substantially free of blood. The invention further relates to a device for the periadventitial delivery of a gene product in which the gene is incorporated into a baculovirus vector from which it can be expressed. HE

HU0302119A 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy HUP0302119A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012997.3A GB0012997D0 (en) 2000-05-26 2000-05-26 Gene delivery
PCT/GB2001/002383 WO2001090390A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy

Publications (2)

Publication Number Publication Date
HUP0302119A2 true HUP0302119A2 (en) 2003-09-29
HUP0302119A3 HUP0302119A3 (en) 2005-12-28

Family

ID=9892534

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302119A HUP0302119A3 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy

Country Status (13)

Country Link
EP (1) EP1283894A1 (en)
JP (1) JP2003533992A (en)
KR (1) KR20030072213A (en)
CN (1) CN1430675A (en)
AU (1) AU2001258657A1 (en)
CA (1) CA2413326A1 (en)
GB (1) GB0012997D0 (en)
HU (1) HUP0302119A3 (en)
IL (1) IL153070A0 (en)
MX (1) MXPA02011517A (en)
NO (1) NO20025657L (en)
PL (1) PL360280A1 (en)
WO (1) WO2001090390A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
KR101699142B1 (en) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 Novel antigen-binding polypeptides and their uses
CN103520735B (en) 2004-12-22 2015-11-25 Ambrx公司 Comprise non-naturally encoded amino acid whose formulations of human growth hormone
JP2008525473A (en) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Modified human growth hormone
CA2590429C (en) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
MX2007007591A (en) 2004-12-22 2007-07-25 Ambrx Inc Methods for expression and purification of recombinant human growth hormone.
SG158148A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2008541769A (en) 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド Improved human interferon molecules and their use
PT2339014E (en) 2005-11-16 2015-10-13 Ambrx Inc Methods and compositions comprising non-natural amino acids
ES2465473T3 (en) 2006-09-08 2014-06-05 Ambrx, Inc. Transcription of arnt suppressor in vertebrate cells
KR20090060294A (en) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 Modified human plasma polypeptide or fc scaffolds and their uses
CN104163864B (en) 2007-03-30 2017-08-01 Ambrx公司 Through modifying the polypeptides of FGF 21 and its purposes
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
JP5547083B2 (en) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド Modified insulin polypeptides and their use
CN103694337B (en) 2008-02-08 2016-03-02 Ambrx公司 Modified leptin polypeptide and its purposes
UA118536C2 (en) 2008-07-23 2019-02-11 Амбркс, Інк. MODIFIED Bovine granulocyte colony-stimulating factor polypeptide and its application
CN101358204B (en) * 2008-08-29 2011-05-18 浙江理工大学 Method for preparing cellular membrane and cellular organelle membrane protein after human enveloped virus budding
KR101647164B1 (en) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 Modified animal erythropoietin polypeptides and their uses
NZ607477A (en) 2008-09-26 2014-09-26 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
CN107056929A (en) 2009-12-21 2017-08-18 Ambrx 公司 Porcine somatotropin polypeptide and its purposes by modification
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX346786B (en) 2010-08-17 2017-03-31 Ambrx Inc Modified relaxin polypeptides and their uses.
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
PL3412302T3 (en) 2014-10-24 2021-11-02 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
CN110637027B (en) 2017-02-08 2024-08-30 百时美施贵宝公司 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof
CN114736929B (en) * 2022-05-16 2023-06-09 睿征医药科技(武汉)有限公司 Composition, method and application for producing recombinant baculovirus in insect cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE287271T1 (en) * 1996-11-01 2005-02-15 Ark Therapeutics Ltd USE OF VEGF FOR PRODUCING A MEDICATION FOR TREATING OR PREVENTING INTIMAL HYPERPLASIA AND ADMINISTRATION DEVICE
DE19735593C2 (en) * 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Coat protein-modified baculovirus vector for gene therapy
EP1100946A1 (en) * 1998-07-24 2001-05-23 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates

Also Published As

Publication number Publication date
JP2003533992A (en) 2003-11-18
NO20025657D0 (en) 2002-11-25
KR20030072213A (en) 2003-09-13
CA2413326A1 (en) 2001-11-29
MXPA02011517A (en) 2004-01-26
EP1283894A1 (en) 2003-02-19
NO20025657L (en) 2002-11-25
CN1430675A (en) 2003-07-16
WO2001090390A9 (en) 2003-01-09
IL153070A0 (en) 2003-06-24
WO2001090390A1 (en) 2001-11-29
GB0012997D0 (en) 2000-07-19
PL360280A1 (en) 2004-09-06
HUP0302119A3 (en) 2005-12-28
AU2001258657A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
HUP0302119A2 (en) Use of baculovirus vectors in gene therapy
DE69932513D1 (en) ADJUSTABLE MOUTH OR NOSE MASK FOR NONINVASIVE VENTILATION OF PATIENTS
TW200509968A (en) Prevention and treatment of synucleinopathic disease
IL163573A0 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
IL157364A0 (en) Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1
HUP0105400A2 (en) Transnasal transportimmunisation with highly adaptable carriers
AU2003210497A8 (en) Gene delivery system and methods of use
ES2167365T3 (en) ADENOVIRAL VECTORS OF ANIMAL ORIGIN AND USE IN GENE THERAPY.
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
MXPA04003668A (en) Type 4 phosphodiesterase inhibitors and uses thereof.
PL369457A1 (en) Hair treatment compositions which provide hair body and which comprise silicone pressure sensitive adhesives
HUP0401867A2 (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
HK1085386A1 (en) Pharmaceuticals comprising shikonins active constituent
WO2002096348A3 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
EP1100815A4 (en) Protease susceptibility ii
DE60034879D1 (en) Lantibiotikum
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
HUP0302738A2 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
AU2001264824A1 (en) Vaccine and gene therapy vector and methods of use thereof
AU2003280688A1 (en) Combination therapy of peptide vaccination and estramustine treatment
WO2002024223A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
WO2003096877A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
GB0228441D0 (en) Splice variant
AU2003257474A8 (en) Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated cpg motifs
EP1185306A4 (en) Use of viral vectors and charged molecules for gene therapy

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees